NeOnc Technologies Reports Updated Clinical Results for Intranasal NEO100

NeOnc Technologies reported updated clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma on December 15, 2025.14

The expanded clinical cohort now includes 25 patients drawn from an ongoing Phase 1/2a trial and compassionate‑use experience.14

Treatment with intranasal NEO100 achieved radiographic remission in 6 of 25 patients (24%) in the updated dataset.14

The study reported a six‑month progression‑free survival (PFS‑6) rate of 44%.1

Long‑term survival outcomes showed that 9 of 25 patients (36%) remained alive at or beyond 18 months after starting NEO100.1

NeOnc reported no significant toxicity with prolonged, chronic intranasal administration of NEO100.14

The company noted that since its prior November 12, 2025 update, one additional patient achieved both durable long‑term survival and radiographic remission, strengthening the observed clinical signal.14

The results are being positioned as evidence that intranasal NEO100 may offer durable disease control and potentially shift management of recurrent IDH1‑mutant gliomas away from purely palliative approaches.14

Data are assessed under RANO criteria and benchmarked against historical outcomes in recurrent high‑grade glioma, where response rates are typically <8% and PFS‑6 ~21–31%, indicating potentially favorable activity for NEO100, though in a small, single‑arm dataset.2

Regulators and stakeholders are watching for the full Phase 2a readout with mature PFS/OS data and randomized trials to confirm efficacy versus standard salvage therapies.2

Sources:

1. https://www.stocktitan.net/news/NTHI/ne-onc-technologies-reports-updated-clinical-3uvlt9f7fec0.html

2. https://www.clinicaltrialvanguard.com/news/neonc-technologies-reveals-updated-clinical-results/

4. https://www.globenewswire.com/news-release/2025/12/15/3205495/0/en/neonc-technologies-reports-updated-clinical-results.html